UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to___________ Commission file number 001-39695 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 83-4364296 (State or other jurisd ...

公司信息 * **公司名称**：Viatris Inc. (NASDAQ:VTRS) * **会议时间**：2023年6月13日 * **会议地点**：Goldman Sachs 44th Annual Global Healthcare Conference * **参会人员**： * Scott Smith - 首席执行官 * Rajiv Malik - 总裁 * Sanjeev Narula - 首席财务官 * Nathan Rich - 高盛分析师 核心观点和论据 * **公司战略**： * 进入战略计划的第二阶段，专注于核心业务增长。 * 通过剥离非核心业务，降低杠杆率，提高股东回报。 * 通过业务发展，包括并购、许可、合作等方式，扩大产品组合。 * **财务状况**： * 预计2024年自由现金流至少为23亿美元。 * 预计EBITDA在4.6至4.9亿美元之间。 * 预计2024年将偿还约23亿美元的债务。 * 预计将把50%的现金流用于股东回报，包括股息和股票回购。 * **产品组合**： * 眼科：Tyrvaya、Oyster Point、其他干眼症药物。 * 消化系统：Symbicort、其他复杂注射剂。 * 皮肤科：其他皮肤科药物。 * **市场表现**： * 预计2024年营收增长3%至5%。 * 预计EBITDA增长4%至5%。 * 预计每股收益增长10%至15%。 其他重要内容 * **剥离业务**： * 预计在2023年底前完成所有剥离。 * 预计将获得约50亿美元的收益。 * 剥离业务将有助于公司专注于核心业务增长。 * **研发**： * 预计研发支出将保持在6%左右。 * 研发支出将支持公司未来的增长。 * **管理层**： * Scott Smith拥有丰富的制药行业经验，曾在辉瑞、Celgene等公司担任高管。 * Rajiv Malik拥有丰富的制药行业经验，曾在Viatris和辉瑞等公司担任高管。 * Sanjeev Narula拥有丰富的财务经验，曾在Viatris和辉瑞等公司担任高管。

Viatris Inc. (NASDAQ:VTRS) Q1 2023 Results Conference Call May 8, 2023 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - Incoming Chief Executive Officer Rajiv Malik - President Sanjeev Narula - Chief Financial Officer Conference Call Participants Glenn Santangelo - Jefferies Chris Schott - JPMorgan Balaji Prasad - Barclays David Amsellem - Piper Sandler Ash Verma - UBS Umer Raffat - Evercore ISI Nathan Rich - Goldman Sachs Group Operator Good morning. My name is Gretch ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to___________ Commission file number 001-39695 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 83-4364296 (State or other juris ...

Viatris Inc. (NASDAQ:VTRS) Q4 2022 Earnings Conference Call February 27, 2023 8:30 AM ET Company Participants Robert Coury - Executive Chairman Scott Smith - Incoming Chief Executive Officer Michael Goettler - Chief Executive Officer Rajiv Malik - President Sanjeev Narula - Chief Financial Officer Jeff Nau - President, Eye Care Division Conference Call Participants Chris Schott - JPMorgan Glenn Santangelo - Jefferies Balaji Prasad - Barclays Jason Gerberry - Bank of America Elliot Wilbur - Raymond James Ash ...

1 This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited. © 2023 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. Q4 and Full Year 2022 Earnings Presentation February 27, 2023 Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Se ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-39695 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 83-4364296 (State or other jurisdiction of incorporation or o ...

Viatris Inc. (NASDAQ:VTRS) 41st Annual J.P. Morgan Healthcare Conference January 11, 2023 6:00 PM ET Company Participants Michael Goettler - CEO Rajiv Malik - President Jeffrey Nau - Head, Eye Care Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Viatris today. From the company, we'll have a presentation from CEO, Michael Goettler and then we're going to open up to a Q&A session with the broader management ...

| --- | --- | --- | --- | --- | |------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Strategic Update: Our Path to Return to Growth | | | | | | November 7, 2022 | | | | | | --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------| | | | ...

Viatris Inc. (NASDAQ:VTRS) Q3 2022 Results Conference Call November 7, 2022 8:30 AM ET Company Participants Bill Szablewski - Head of Global Capital Markets Robert Coury - Executive Chairman Michael Goettler - Chief Executive Officer Rajiv Malik - President Dr. Jeff Nau - Oyster Point CEO Sanjeev Narula - Chief Financial Officer Conference Call Participants Elliot Wilbur - Raymond James Umer Raffat - Evercore Michaela Diverio - Barclays Chris Schott - JPMorgan Gary Nachman - BMO Capital Markets Ash Verma - ...